Santen Pharmaceutical (OTCMKTS:SNPHY) Trading Down 5.7% – Here’s Why

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s share price was down 5.7% during mid-day trading on Thursday . The stock traded as low as $11.85 and last traded at $11.85. Approximately 170 shares changed hands during trading, a decline of 99% from the average daily volume of 14,562 shares. The stock had previously closed at $12.57.

Analyst Ratings Changes

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

Santen Pharmaceutical Trading Up 2.7%

The business has a 50-day moving average of $11.25 and a two-hundred day moving average of $10.86. The firm has a market cap of $3.88 billion and a P/E ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.